Home / Mesothelioma / Prognosis

Prognosis

A mesothelioma diagnosis comes with many important questions. Perhaps the most crucial question is – what is the prognosis? In fact, the prognosis of mesothelioma varies depending on a number of variables. These variables include:

1. The patient – their age, biology, and state of health
2. The cancer – has the mesothelioma spread or is it localized when it is diagnosed and what is the cell type
3. The treatment or treatments selected
4. The expertise of the treatment team (doctors and other clinicians)

The Patient’s Health

A patient’s general state of health is an important prognostic factor in fighting any disease and mesothelioma is no exception. In addition, a patient’s biology or physiology also plays a role. For example, will chemotherapy work or can it be tolerated? Does the patient have a heart condition so that surgery is not an option? How will the patient’s biology interact with the treatment? The answers to these questions can all play a role in the prognosis.

The Cancer

The spread or lack of spread of the cancer is also an important factor. If mesothelioma is localized it can be easier to treat. In fact, surgery is usually only an option if the cancer has not metastasized. If it has spread then treatment options may be more limited. In addition, there are three cell types of mesothelioma – epithelioid, biphasic, and sacramatoid. The first, epithelioid, often has the best prognosis of the three.

The Treatment

The treatment or therapies selected is also important. Patients can select from conventional therapies (radiation, chemo, and surgery), clinical trials or integrative or alternative modalities. Not every therapy works in every patient. There is an important connection between a person’s physiology, cancer and the treatments selected. The interchange or intersection of these three factors often dictate what the treatment outcome and prognosis will be. Unfortunately, it is often difficult to predict because how a tumor or a treatment acts in a patient’s body is often not known until after the fact.

The Doctors’ Expertise

The last factor is the expertise of your doctors or licensed care givers. How these people do their jobs can be a key factor in prognosis. Are the surgeons experienced with mesothelioma? For example, what is their mortality rate for surgery? The smallest rate bodes better than the highest rate. Also, what options can these treaters suggest? Do they only offer chemo or can they offer a wide range of different modalities and treatment options. All these factors play a role in the prognosis of mesothelioma.

Below are some more details about the prognosis for mesothelioma.

Prognosis of Pleural Mesothelioma

The prognosis of pleural mesothelioma with standard treatment is typically not great.   Median overall survival is a little over a year.  However, there are a number of factors that affect prognosis.

A number of studies have been performed over the years to determine what treatments are optimum for mesothelioma and what factors lead to a better prognosis. Below, we report on several of these.

In a September 2016 Austrian study, a total of 210 patients with malignant pleural mesothelioma were followed.

• 167 (79.5%) were men and 43 (20.5%) were women
• The average age was 67 at the time of diagnosis
• Asbestos exposure was confirmed in 109 (69.4%) patients
• The majority of patients had epithelioid cell type (67.2%)
• Sarcomatoid comprised 16 (7.6%)
• Biphasic was found in 28 patients (13.3%)
• In 25 patients, the cell type was not specified

Data about survival was available for 185 patients. The study found:

• Median overall survival was 19.1 months.
• Pleural mesothelioma patients with early-stage disease (stages I, II) had an overall survival of 26.4 months.
• Pleural mesothelioma patients with late-stage disease (stages III, IV) had an overall survival of 13.0 months .
• Patients with epithelioid cell type had overall survival of 25.1 months.
• Patients with sarcomatoid or biphasic cell type had overall survival of 10.2 months.
• There was no survival difference between males and females.
• There was no survival difference between patients below or above the age of 65 years.
• Survival was significantly better in patients undergoing surgery. However, these patients were significantly younger, had earlier-stage disease, better performance status, and more often had epithelioid subtype.

The study concluded that factors that indicated a better prognosis included: higher Karnofsky score, earlier stage disease, epithelioid cell type, and surgery within multimodality treatment.

• Management of malignant pleural mesothelioma – part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. Klikovits T, et al., Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34.

Prognosis of Peritoneal Mesothelioma

The prognosis of peritoneal mesothelioma has become much better with the advent of surgery and HIPEC.  The following studies illustrate the improvements in prognosis over the last several years.

Peritoneal Mesothelioma Prognosis with Chemotherapy

In a 2011 Greek Study, chemotherapy was used to treat peritoneal mesothelioma patients.  Six patients with peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. The estimated median overall survival was 24 months.

• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Lainakis G, et al., Tumori. 2011 Jan-Feb;97(1):25-9.

Peritoneal Mesothelioma Prognosis with HIPEC

An April 2014 United States Study examined 65 patients with pleural mesothelioma who underwent surgery and HIPEC (hyperthermic intraperitoneal chemoperfusion) between 2001 and 2010.

What is HIPEC for Mesothelioma?

HIPEC is where heated chemotherapy is used to bath the surgical cavity putting the chemo in direct contact where the tumor cells remain.  The study found that overall mesothelioma survival was 46.2 months.  The study also found that although survival was better, there were side effects associated with this treatment approach that included:

• Six percent of the patients died within 60 days.
• Of the 65 patients, 91 % were admitted to the intensive care unit (ICU) postoperatively, with median hospital length of 12 days.
• A total of 12 patients (18 %) underwent reoperation: four patients (33 %) for enteric leak, 1 patient (8 %) for an intra-abdominal abscess, and seven patients (58%) for other reasons.

Factors that contributed to a poor prognosis included:

• Older patient
• More widespread tumors
• More aggressive cell type
• Incomplete surgery
• Post-operative infection

The study concluded that better prognosis is associated with patients who have the epithelioid cell type, lower volume of tumor, and more effective surgery (most tumor removed).

• Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D., et al., Ann Surg Oncol. 2014 Apr;21(4):1159-65.

Next: Treatment

Related Posts

Latest Classification Updates for Mesothelioma In Situ - There are new guidelines on the diagnosis and classification of mesothelioma in situ. A new article in the Journal of Cancer Metastasis and Treatment talks about why these updates are important. The latest updates were first published by the World Health Organization (WHO). The previous WHO classification of pleural mesothelioma included three histological subtypes. But WHO recently recognized mesothelioma in situ as a fourth mesothelioma subtype. Pathologists can tell the difference between the subtypes by looking at the cells under a microscope. Each subtype has a slightly different cell shape, growth pattern, and nuclear characteristics. The fourth mesothelioma subtype is a very early form of mesothelioma. Previous studies suggest that it may be an early sign of mesothelioma. If patients … Continue reading Latest Classification Updates for Mesothelioma In Situ »

High-Resolution Imaging for Mesothelioma Staging and Diagnosis - High-resolution imaging is one of the most important tools for a clinician. A new report in the AME Surgical Journal shows the importance of better clinical imaging. It is key for accurate diagnosis and staging of malignant mesothelioma. Malignant pleural mesothelioma is a complex disease. Mesothelioma diagnosis and accurate staging are often difficult to pin down. And the diagnosis is further complicated by different disease subtypes. Higher resolution diagnostic imaging plays an important role in diagnosis and staging. It shows tumor thickness or volumetric data. Future updates to the cancer staging system may use clinical imaging benchmarks. Importance and Use of Clinical Imaging Mesothelioma causes significant morbidity and mortality. And it remains a challenging disease to diagnose and stage accurately. … Continue reading High-Resolution Imaging for Mesothelioma Staging and Diagnosis »

Improving the Health and Lifestyle of Mesothelioma Patients - Mesothelioma patients often have bad health outcomes and poor health-related quality of life. Common symptoms reported by mesothelioma patients are appetite loss and weight loss. Poor nutrition and low body mass index are also common. Most mesothelioma patients would welcome exercise and nutrition advice. This advice might help them cope with their cancer, and its symptoms, better. But there are barriers to getting this kind of information into the hands of people who need it. A clinical team from North Tyneside Hospital in the United Kingdom is looking into this. They have a new study called Help-Meso: Health and Lifestyle of Patients with Mesothelioma. Patients, caregivers, and health professionals will take part in the study. Symptoms of Pleural Mesothelioma and … Continue reading Improving the Health and Lifestyle of Mesothelioma Patients »

Predicting Survival in Patients with Malignant Pleural Mesothelioma - Researchers found a new way of predicting survival in malignant pleural mesothelioma patients. The prognostic model takes information from the health record to predict survival. Mesothelioma is a rare form of cancer caused by exposure to asbestos. The new prognostic model can help doctors decide on the best treatment plan. This is important for newly-diagnosed patients. And it will have a big impact on their prognosis and quality of life. Many factors can affect a malignant mesothelioma prognosis. Some relate to the patient’s overall health and disease stage or type. While others have to do with the type of treatment the patient undergoes. Several prognostic models have been developed for mesothelioma. These all include information from the patient’s record. And … Continue reading Predicting Survival in Patients with Malignant Pleural Mesothelioma »

New Tool Measures Past Exposure to Asbestos - A new Italian study supports the most reliable tool for determining past exposure to asbestos. The study has confirmed what thousands of mesothelioma patients already know. Exposure to asbestos puts them at high risk for malignant mesothelioma. Asbestos is a naturally occurring mineral that has been found throughout the world. It was once called the “magic mineral” because of its seemingly magical properties. Because of its heat-resistant properties, it served as an insulator in factories, schools, homes, and ships. Thousands of workers have come in contact with the material daily, in some cases, for decades. Asbestos is toxic and cancer-causing for human beings. It causes mesothelioma and other asbestos-related diseases. Generally, those who develop asbestos-related diseases show no signs of … Continue reading New Tool Measures Past Exposure to Asbestos »

Mesothelioma Multidisciplinary Team Improves Patient Outcomes - Oxford University Hospital found that a multidisciplinary team is best in mesothelioma care. This treatment approach includes many doctors who are experts in different specialties. Together, they offer the best clinical decision-making team, and they improve patient outcomes. There are many factors that impact clinical decision-making. But this new report focuses on which factors improve mesothelioma patient care. And which factors support informed decisions about follow-up care. Results showed that the most important factor is a strong team of doctors. Two Heads are Better than One Malignant pleural mesothelioma is a rare, incurable cancer coming from asbestos exposure. Patients have a poor prognosis and a median survival rate of 8 to 14 months. Differences in mesothelioma clinical decision-making are common. … Continue reading Mesothelioma Multidisciplinary Team Improves Patient Outcomes »

Prognostic Factors Forecast the Future for Women with Mesothelioma - A new study in the World Journal of Surgical Oncology examines mesothelioma prognostic factors. Prognostic factors are measurable traits that can be used to estimate the chance of recovery. They can also measure the chance of mesothelioma recurring or coming back. In other words, prognostic factors can help predict the course of the disease and the future outcome. Prognostic factors are available at the time of diagnosis. They can include patient characteristics such as age, ethnicity, sex, or smoking status. And they also include disease characteristics such as disease stage or type. For mesothelioma, they may even involve the amount of asbestos exposure. The key to prognostic factors is that they must be measurable. Clinicians need a number, or a … Continue reading Prognostic Factors Forecast the Future for Women with Mesothelioma »

Mesothelioma and the Promising New Hippo Biomarker - A new review in Targeted Oncology looks at a promising new Hippo biomarker in malignant pleural mesothelioma. The new biomarker is rooted in the mesothelioma molecular pathway. A molecular pathway is how molecules work together inside your body. These pathways control cell function. And they are important in developing mesothelioma treatments. Think of molecular pathways as the airport tower controller. These pathways tell mesothelioma treatments where to go and what to do in the body. If doctors can understand how pathways work, they can develop better treatments. The goal is to develop more, and more effective, mesothelioma treatments. Promising Hippo Pathway in Malignant Pleural Mesothelioma While several drugs have been approved for treating mesothelioma, there aren’t a lot. This is … Continue reading Mesothelioma and the Promising New Hippo Biomarker »

Easing the Painful Symptoms of Malignant Pleural Mesothelioma - Malignant pleural mesothelioma is an aggressive and rare cancer. There is new hope for reducing the painful symptoms of malignant pleural mesothelioma. A new study in BMC Cancer looked at treatments and the symptom burden of malignant pleural mesothelioma in Europe. The symptoms of malignant pleural mesothelioma are very hard. But there are treatments available to improve quality of life. New data proves that chemotherapy eases mesothelioma symptoms. And it is most likely to improve and maintain health-related quality of life. The Long Journey of Mesothelioma Mesothelioma is the asbestos-caused cancer. Malignant pleural mesothelioma is the most common form of mesothelioma. It accounts for over 90,000 deaths per year globally. It takes a very long time to diagnose mesothelioma. Usually, … Continue reading Easing the Painful Symptoms of Malignant Pleural Mesothelioma »

Amount of Asbestos Exposure and Mesothelioma Survival - Many clinical researchers have asked the question: “Does the amount of asbestos exposure affect prognosis?” But every researcher comes to a slightly different conclusion. Many have looked at this question. But few can agree on the answer. Recently there were two articles in the Journal of Thoracic Oncology that proposed two opposite endings on this topic. One said that “the amount of asbestos in the lungs may directly correlate with shorter survival in patients with mesothelioma.” And the other said, “the amount of asbestos in the lungs does not influence survival.” A new article in the International Association for the Study of Lung Cancer compares notes from all the different studies. Dr. Michele Carbone from the University of Hawaii Cancer … Continue reading Amount of Asbestos Exposure and Mesothelioma Survival »